Estadísticas

 array:18 [
  "pii" => "X1699258X18624044"
  "issn" => "1699258X"
  "estado" => "S300"
  "fechaPublicacion" => "2018-01-01"
  "documento" => "article"
  "subdocumento" => "fla"
  "cita" => "Reumatol Clin. 2018;14 Supl 1:22-7"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1984
    "formatos" => array:3 [
      "EPUB" => 111
      "HTML" => 530
      "PDF" => 1343
    ]
  ]
  "itemSiguiente" => array:14 [
    "pii" => "X1699258X18624036"
    "issn" => "1699258X"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "documento" => "article"
    "subdocumento" => "fla"
    "cita" => "Reumatol Clin. 2018;14 Supl 1:28-34"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3266
      "formatos" => array:3 [
        "EPUB" => 156
        "HTML" => 1172
        "PDF" => 1938
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Rol de la interleucina-17 en otras enfermedades y comorbilidades"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "28"
          "paginaFinal" => "34"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Role of interleukin-17 in other diseases and comorbidities"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Rubén Queiro-Silva"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Rubén"
              "apellidos" => "Queiro-Silva"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1699258X18624036?idApp=UINPBA00004M"
    "url" => "/1699258X/00000014000000S1/v0_201803261703/X1699258X18624036/v0_201803261703/es/main.assets"
  ]
  "itemAnterior" => array:14 [
    "pii" => "X1699258X18624001"
    "issn" => "1699258X"
    "estado" => "S300"
    "fechaPublicacion" => "2018-01-01"
    "documento" => "article"
    "subdocumento" => "fla"
    "cita" => "Reumatol Clin. 2018;14 Supl 1:16-21"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1532
      "formatos" => array:3 [
        "EPUB" => 117
        "HTML" => 491
        "PDF" => 924
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Eficacia y seguridad de los fármacos inhibidores de la interleucina-17 en la espondilitis anquilosante"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "16"
          "paginaFinal" => "21"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Efficacy and safety of drugs that inhibit interleukin-17 in ankylosing spondylitis"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Victoria Navarro-Compán"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Victoria"
              "apellidos" => "Navarro-Compán"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1699258X18624001?idApp=UINPBA00004M"
    "url" => "/1699258X/00000014000000S1/v0_201803261703/X1699258X18624001/v0_201803261703/es/main.assets"
  ]
  "es" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Eficacia y seguridad de los fármacos inhibidores de la interleucina-17 en la artritis psoriásica"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "22"
        "paginaFinal" => "27"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "José Antonio Pinto Tasende"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "José Antonio"
            "apellidos" => "Pinto Tasende"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Servicio de Reumatolog&#237;a&#44; INIBIC-Complejo Hospitalario Universitario A Coru&#241;a&#44; A Coru&#241;a&#44; Espa&#241;a"
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Efficacy and safety of interleukin-17 inhibiting drugs in psoriatic arthritis"
      ]
    ]
    "pdfFichero" => "273v14nExtr.1a90462404pdf001.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec968536"
          "palabras" => array:7 [
            0 => "Artritis psori&#225;sica"
            1 => "Interleucina 17"
            2 => "Secukinumab"
            3 => "Ixekizumab"
            4 => "Brodalumab"
            5 => "Eficacia"
            6 => "Seguridad"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec968537"
          "palabras" => array:7 [
            0 => "Psoriatic arthritis"
            1 => "Interleukin&#45;17"
            2 => "Secukinumab"
            3 => "Ixekizumab"
            4 => "Brodalumab"
            5 => "Efficacy"
            6 => "Safety"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "En los &#250;ltimos a&#241;os se ha avanzado en el entendimiento de los mecanismos patog&#233;nicos de la artritis psori&#225;sica&#44; dando protagonismo a citocinas implicadas en el eje interleucina &#40;IL&#41;-23&#47;Th17&#44; fundamentalmente la IL&#45;17&#46; As&#237;&#44; se han desarrollado f&#225;rmacos que inhiben la acci&#243;n de esta citocina de forma eficaz y segura a tenor de los resultados de los distintos ensayos cl&#237;nicos realizados&#46; Este art&#237;culo revisa la eficacia terap&#233;utica del secukinumab&#44; ixekizumab y brodalumab en el tratamiento de la artritis psori&#225;sica&#44; as&#237; como la tolerabilidad y las seguridad de estos f&#225;rmacos&#44; y que muestran los datos de los ensayos cl&#237;nicos que se han comunicado en distintas publicaciones o presentado en los &#250;ltimos congresos de reumatolog&#237;a y que demostraron que&#44; en comparaci&#243;n con placebo&#44; son eficaces para mejorar los signos y s&#237;ntomas de la artritis psori&#225;sica en pacientes con enfermedad activa a pesar del tratamiento previo con f&#225;rmacos antiinflamatorios no esteroideos&#44; f&#225;rmacos reum&#225;ticos modificadores de la enfermedad o inhibidores del factor de necrosis tumoral alfa&#46; Aunque ser&#225; la pr&#225;ctica cl&#237;nica la que dir&#225; a medio y largo plazo cu&#225;l es su sitio en el arsenal terap&#233;utico de la artritis psori&#225;sica&#44; los datos cl&#237;nicos actuales son muy prometedores&#46;"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "In recent years&#44; our understanding of the pathogenic mechanisms of psoriatic arthritis &#40;PsA&#41; has improved&#44; lending prominence to cytokines involved in the interleukin-23 &#40;IL&#45;23&#41;&#47;Th17 axis&#44; basically IL&#45;17&#46; Consequently&#44; drugs have been developed that effectively and safely inhibit the action of that cytokine&#44; as demonstrated by the results of the various clinical trials carried out&#46; This article reviews the therapeutic efficacy of secukinumab&#44; ixekizumab and brodalumab in the treatment of PsA&#44; in addition to the tolerability and safety of these agents&#46; We provide the data of the clinical trials reported in different publications or presented at the latest rheumatology meetings&#44; that reveal their efficacy&#44; as compared to placebo&#44; in improving the signs and symptoms of PsA in patients with active disease&#44; despite previous treatment with nonsteroidal anti-inflammatory drugs&#44; disease-modifying antirheumatic drugs or tumor necrosis factor a inhibitors&#46; The findings in clinical practice over the medium and long term will indicate their place in the therapeutic arsenal of PsA&#46; However&#44; the clinical data at this time are very promising&#46;"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/1699258X/00000014000000S1/v0_201803261703/X1699258X18624044/v0_201803261703/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "73100"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Interleucina-17 A&#58; Fundamentos b&#225;sicos y efectos terap&#233;uticos de su inhibici&#243;n en la espondilitis anquilosante y la artritis psori&#225;sica"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/1699258X/00000014000000S1/v0_201803261703/X1699258X18624044/v0_201803261703/es/273v14nExtr.1a90462404pdf001.pdf?idApp=UINPBA00004M&text.app=https://reumatologiaclinica.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1699258X18624044?idApp=UINPBA00004M"
]